PROLOR Biotech reports anti-obesity drug positive preclinical trial results

PROLOR Biotech uses patented CTP technology and its Reversible PEGylation technology to develop longer-acting, proprietary versions of already approved therapeutic proteins to increase half-life of the drug candidate.

The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily.

In the study, OXY-RPEG injected either once or twice weekly demonstrated higher weight loss, reduction of food intake and duration of weight loss activity compared with oxyntomodulin injected twice daily.

PROLOR CEO Abraham Havron said they believe that oxyntomodulin’s natural role as an appetite suppressant and its anticipated favorable safety profile make it a potential weight loss therapy for the millions of obese patients who lack safe and effective treatment options.

PROLOR president Shai Novik said these positive results provide us with the confidence to initiate additional Reversible PEGylation development initiatives for peptides and small molecules targeting high potential market segments.